Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2197-2203

  Chen, Jun ^a   Wu, Fang ^a   Pei, Hong Lei ^a   Gu, Wen Dong ^a   Ning, Zhong Hua ^a   Shao, Ying Jie ^a   Huang, Jin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cox 2; Esophageal cancer; P53; Prognosis; Relevance

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P53;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR RECURRENCE;

EID: 84940047167     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3624     Document Type: Article

References (30)

1. Huang JX, Chen WC, Lin M, Zhang YL, Li FY, Song ZX, Xiao W, Chen P, Qian RY, Salminen E, et al: Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma. Dis Esophagus 25: 121-129, 2012.
2. Meng XY, Zhu ST, Zong Y, Wang YJ, Li P and Zhang ST: Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma. Dis Esophagus 24: 444-449, 2011.
3. Surget S, Khoury MP and Bourdon JC: Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. Onco Targets Ther 7: 57-68, 2014.
4. Chandrasekharan NV and Simmons DL: The cyclooxygenases. Genome Biol 5: 241, 2004.
5. Chen LQ: Understanding and appraisal of the new TNM classification for esophageal cancer in the AJCC cancer staging manual (7th edition). Zhonghua Zhong Liu Za Zhi 32: 237-240, 2010 (In Chinese).
6. Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas SA, Aamodt K, et al: Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci USA 106: 12115-12120, 2009.
7. Huang H, Wang LF, Tian HM, Liu Y, Li M, Qu P, Wang WR and Zhang W: Expression of retinoic acid receptor-beta mRNA and p16, p53, Ki67 proteins in esophageal carcinoma and its precursor lesions. Zhonghua Zhong Liu Za Zhi 27: 152-155, 2005 (In Chinese).
8. Do PM, Varanasi L, Fan SQ, Li CY, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, et al: Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26: 830-845, 2012.
9. Lee MH and Lozano G: Regulation of the p53-MDM2 pathway by 14-3-3 and other proteins. Semin Cancer Biol 16: 225-234, 2006.
10. Kirsch DG and Kastan MB: Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol 16: 3158-3168, 1998.
11. Fagundes RB, Mello CR, Tollens P, Pütten ACK, Wagner MB, Moreira LF and Barros SG: P53 protein in esophageal mucosa of individuals at high risk of squamous cell carcinoma of the esophagus. Dis Esophagus 14: 185-190, 2001.
12. Han U, Can OI, Han S, Kayhan B and Onal BU: Expressions of p53, VEGF C, p21: Could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus 20: 379-385, 2007.
13. Ye B, Wang X, Yang Z, Sun Z, Zhang R, Hu Y, Lu Y and Du J: P53 and p73 expression in esophageal carcinoma correlate with clinicopathology of tumors. Hepatogastroenterology 59: 2192-2195, 2012.
14. Chino O, Kijima H, Shimada H, Nishi T, Tanaka H, Kise Y, Kenmochi T, Himeno S, Machimura T, Tanaka M, et al: Accumulation of p53 in esophageal squamous cell carcinoma. Int J Mol Med 8: 359-363, 2001.
15. Jin Y, Zhang W and Liu B: Abnormal expression of p53, Ki67 and iNOS in human esophageal carcinoma in situ and pre-malignant lesions. Zhonghua Zhong Liu Za Zhi 23: 129-131, 2001 (In Chinese).
16. Feletou M, Huang Y and Vanhoutte PM: Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164: 894-912, 2011.
17. O'Banion MK: Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 13: 45-82, 1999.
18. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol 270: G393-G400, 1996.
19. Willoughby DA, Moore AR and Colville-Nash PR: COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355: 646-648, 2000.
20. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T and Lala PK: Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 92: 1115-1128, 2012.
21. Misra S and Sharma K: COX-2 signaling and cancer: New players in old arena. Curr Drug Targets 15: 347-359, 2014.
22. Okumura H, Uchikado Y, Setoyama T, Matsumoto M, Owaki T, Ishigami S and Natsugoe S: Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today 44: 421-428, 2014.
23. Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E and Majima M: Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema. Lab Invest 91: 1314-1325, 2011.
24. Zhou BT, Yang W, Xu XH, Ai YG, Li XL and Huang YJ: Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi 13: 699-702, 2010 (In Chinese).
25. Prins MJ, Verhage RJ, ten Kate FJ and van Hillegersberg R: Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg 16: 956-966, 2012.
26. Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, Tanière P, Chariot A, Scoazec JY, de Moura Gallo CV, et al: Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 25: 5708-5718, 2006.
27. Song J, Wei Y, Chen Q and Xing D: Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts. J Photochem Photobiol B 134: 27-36, 2014.
28. Cheng AS, Yu J, Lai PB, Chan HL and Sung JJ: Cox-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun 374: 175-180, 2008.
29. Choi EM, Kim SR, Lee EJ and Han JA: Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53. Biochim Biophys Acta 1793: 1354-1365, 2009.
30. Ma XL, XS G and Sun HJ: Advance in research on relations between cyclooxygenase-2 and P53 during inflammatory stress and carcinogenesis. Int J Genet 32: 372-376, 2009 (In Chinese).